@article{ajmcr2017582,
author={{Moghadam, Arash Dooghaie and Keipourfard, Ali and Arjmand, Yasaman},
title={Unruptured Vertebral Artery Dissecting Aneurysms: Approach Strategy by Retrospective Analysis},
journal={American Journal of Medical Case Reports},
volume={5},
number={8},
pages={202--204},
year={2017},
url={http://pubs.sciepub.com/ajmcr/5/8/2},
issn={2374-216X},
abstract={<b>Objectives</b><b>:</b><b> </b>The natural course of un-ruptured vertebral artery dissecting aneurysms (VADAs) is not completely clear. We aim to retrospectively develop a strategy for treating un-ruptured VADAs based on long-term follow-up. <b>Methods</b><b>:</b><b> </b>We retrospectively studied 35 patients with un-ruptured VADAs. The initial symptom of 20 patients was headache, followed by ischemic symptoms and mass effect in 11 and 4 patients respectively. All of the patients underwent Magnetic Resonance Imaging (MRI) and Magnetic Resonance Angiography (MRA) at the time of admission and 2 weeks and 1, 4, 6, 12, and 24 months after initial presentation. Asymptomatic patients with enlarging dissection site defined on MRI and MRA, received further treatment and work up. <b>Results</b><b>:</b><b> </b>Two patients received emergency intervention due to symptom exacerbation and unstable status. The other 33 patients underwent conservative management. Lesion enlargement was observed in 2 cases during imaging follow up. In follow up period, additional interventions including dissection trap by surgery and coil embolization were conducted in 1 and 3 patients respectively. Other 31 patients remain symptom free and were managed conservatively. Dissection site remained unchanged in majority of patients (68.57%), improved in 28.57% and disappeared in 2.85% of the patients. Ten patients with recurrent ischemic attacks underwent anti-platelet therapy, without any bleeding complaint or permanent neurological deficits. <b>Conclusion</b><b>: </b>The nature of an un-ruptured VADA is not highly aggressive. However, enlarged dissection site without new manifestations, occlusion is recommended. Also, anti-platelet therapy is suggested in patients with recurrent ischemic attacks.},
doi={10.12691/ajmcr-5-8-2}
publisher={Science and Education Publishing}
}